<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310073</url>
  </required_header>
  <id_info>
    <org_study_id>bOPV 0416</org_study_id>
    <nct_id>NCT03310073</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV</brief_title>
  <official_title>Immunogenicity and Safety Profile of Primary Dose of Bivalent OPV (bOPV Bio Farma) Given Simultaneously With Pentabio® And Inactivated Poliovirus Vaccine (IPV) at the 4th Visit in Indonesian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess protectivity following four doses of bOPV which given simultaneously
      with Pentabio® and 1 dose of IPV at the 4th visit
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe serological response after four doses of bOPV with 1 dose of IPV. To describe the
      antibody status to polio 60 days after birth dose of bOPV To assess the safety of bOPV which
      given simultaneously with Pentabio® and 1 dose 1 dosde of IPV at the 4th visit
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with anti polio titer ≥ 8 for type 1, 2 and type 3</measure>
    <time_frame>30 days after the last vaccination</time_frame>
    <description>Evaluate protectivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of infants with increasing antibody titer &gt;= 4 times</measure>
    <time_frame>30 days after the last vaccination</time_frame>
    <description>Serological response after four doses of bOPV with 1 dose of IPV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of infants with transition of seronegative to seropositive</measure>
    <time_frame>30 days after the last vaccination</time_frame>
    <description>Serological response after four doses of bOPV with 1 dose of IPV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) after four doses of bOPV with 1 dose of IPV</measure>
    <time_frame>30 days after the last vaccination</time_frame>
    <description>Geometric Mean Titer (GMT) 30 days after the last vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of systemic adverse events (AEs) after each dose of bOPV, which given simultaneously with Pentabio and 1 dose of IPV</measure>
    <time_frame>first 30 minutes, 24hour, 48hour, 72hour and 30 days after vaccination.</time_frame>
    <description>Assess the safety of bOPV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAE) which occured during the study</measure>
    <time_frame>30 days after the last vaccination</time_frame>
    <description>Assess the safety of bOPV</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>bOPV (bivalent OPV Bio Farma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.
The subject received bOPV, Pentabio and IPV according to the study schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bOPV</intervention_name>
    <description>Batch Number: 2042015</description>
    <arm_group_label>bOPV (bivalent OPV Bio Farma)</arm_group_label>
    <other_name>bivalent Oral Polio Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentabio</intervention_name>
    <description>Batch number: 5050115 The vaccine shall be given intramuscularly.</description>
    <arm_group_label>bOPV (bivalent OPV Bio Farma)</arm_group_label>
    <other_name>DTP-HB-Hib Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPV</intervention_name>
    <description>The vaccine shall be given intramuscularly.</description>
    <arm_group_label>bOPV (bivalent OPV Bio Farma)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, full term, newborns infants.

          -  Newborns residing within a relatively short and easily accessible distance (&lt;30 km)
             from the study clinic(s) and not planning to travel away during the entire study
             period.

          -  Infant born after 37 weeks of pregnancy

          -  Infant weighing 2.5 kg or more at birth (Birth weight &gt; 2.5 kg)

          -  Healthy newborns, with no history of asphyxia or meconium aspiration.

          -  Father, mother or legally acceptable representative properly informed about the study
             and having signed the informed consent form.

          -  Parents will commit themselves to comply with the indications of the investigator and
             with the schedule of the trial.

          -  Mother at least elementary school graduate

        Exclusion Criteria:

          -  Child concomitantly enrolled or scheduled to be enrolled in another trial

          -  Known history of congenital or acquired immunodeficiency (including HIV infection)

          -  Evolving moderate or severe illness, especially infectious diseases or fever (axillary
             temperature ≥ 37.5°C )

          -  Newborns requiring hospitalization at birth.

          -  Infant immunized with non-scheduled bOPV or IPV during trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kusnandi Rusmil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasan Sadikin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hasan Sadikin Hospital</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

